Hua Medicine is an innovative pharmaceutical company based in Shanghai, focusing on the development and commercialization of new therapies to address unmet medical needs, particularly in diabetes care. Their core product, Dorzagliatin (HMS5552), is a novel oral medication designed as a glucokinase activator (GKA) that enhances glucose sensitivity in patients with type 2 diabetes. This medication aims to restore the function of glucokinase, which is often impaired in diabetic patients, thereby improving blood glucose homeostasis. Dorzagliatin has received regulatory approval in China and is being promoted in collaboration with Bayer to benefit diabetes patients and their families.

In addition to Dorzagliatin, Hua Medicine is also developing mGluR5 NAM, a potential new drug for treating levodopa-induced movement disorders in Parkinson's disease. The company employs advanced research methodologies, including the use of computer simulations for pharmacokinetic and pharmacodynamic modeling, to enhance the efficiency of drug development. Their innovative approach integrates artificial intelligence and big data analysis to classify type 2 diabetes patients effectively, guiding personalized treatment strategies. This commitment to scientific research and innovation positions Hua Medicine as a leader in diabetes care and other therapeutic areas.

China

Hua Medicine is a leading clinical-stage, innovative drug development company in China, focusing on novel therapies for the treatment of diabetes and CNS disorders. 

In order to meet the highest international standards, Hua Medince developed a powerful internal research quality supervision system Q (QC/QA) based on the advanced open innovation model VIC (VC + IP + CRO).

275 Ai Di Sheng Road, Zhangjiang Hi-Tech Park, Pudong, Shanghai 201203, Shanghai, Shanghai CN

Hua Medicine

Company Details